JPWO2022066734A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022066734A5 JPWO2022066734A5 JP2023542834A JP2023542834A JPWO2022066734A5 JP WO2022066734 A5 JPWO2022066734 A5 JP WO2022066734A5 JP 2023542834 A JP2023542834 A JP 2023542834A JP 2023542834 A JP2023542834 A JP 2023542834A JP WO2022066734 A5 JPWO2022066734 A5 JP WO2022066734A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- present
- independently selected
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063082324P | 2020-09-23 | 2020-09-23 | |
| US63/082,324 | 2020-09-23 | ||
| US202063092970P | 2020-10-16 | 2020-10-16 | |
| US63/092,970 | 2020-10-16 | ||
| PCT/US2021/051504 WO2022066734A1 (en) | 2020-09-23 | 2021-09-22 | Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023543528A JP2023543528A (ja) | 2023-10-16 |
| JPWO2022066734A5 true JPWO2022066734A5 (https=) | 2024-10-02 |
| JP2023543528A5 JP2023543528A5 (https=) | 2024-10-02 |
| JP7797513B2 JP7797513B2 (ja) | 2026-01-13 |
Family
ID=78135207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023542834A Active JP7797513B2 (ja) | 2020-09-23 | 2021-09-22 | がんの処置に有用なピロロ［３，２－ｃ］ピリジン－４－オン誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230364070A1 (https=) |
| EP (1) | EP4217070A1 (https=) |
| JP (1) | JP7797513B2 (https=) |
| KR (1) | KR20230094197A (https=) |
| AU (1) | AU2021347288A1 (https=) |
| CA (1) | CA3196712A1 (https=) |
| CL (1) | CL2023000856A1 (https=) |
| IL (1) | IL301532A (https=) |
| MX (1) | MX2023003362A (https=) |
| TW (1) | TW202229272A (https=) |
| WO (1) | WO2022066734A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021330835B2 (en) | 2020-08-24 | 2023-12-14 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
| WO2022066835A1 (en) | 2020-09-23 | 2022-03-31 | St. Jude Children's Research Hospital, Inc. | Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| WO2023173083A1 (en) * | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
| US20250197391A1 (en) | 2022-03-24 | 2025-06-19 | Scorpion Therapeutics, Inc. | Methods of synthesizing egfr inhibitors |
| US20250282795A1 (en) * | 2022-04-20 | 2025-09-11 | Celyn Therapeutics, Inc. | EGFR Inhibitors in cancer treatment |
| CN121909190A (zh) | 2023-06-08 | 2026-04-21 | 安塔列斯疗法股份有限公司 | 1,5-二氢-4H-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗 |
| CN121712773A (zh) * | 2023-06-08 | 2026-03-20 | 安塔列斯疗法股份有限公司 | 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗 |
| WO2025049904A1 (en) | 2023-08-31 | 2025-03-06 | Scorpion Therapeutics, Inc. | Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation |
| EP4534085A1 (en) | 2023-10-03 | 2025-04-09 | Scorpion Therapeutics, Inc. | Compounds for use in methods of treating cancer |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6906194B2 (en) | 2003-10-08 | 2005-06-14 | Massachusetts Instititue Of Technology | Fluorescence assay for kinase activity |
| US7964729B2 (en) | 2006-08-28 | 2011-06-21 | Massachusetts Institute Of Technology | Sox-based kinase sensor |
| WO2012087943A2 (en) | 2010-12-20 | 2012-06-28 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| WO2013092512A1 (en) | 2011-12-21 | 2013-06-27 | Bayer Intellectual Property Gmbh | Substituted benzylpyrazoles |
| WO2013167698A1 (en) | 2012-05-11 | 2013-11-14 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| US9604980B2 (en) * | 2012-11-07 | 2017-03-28 | Nerviano Medical Sciences S.R.L. | Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors |
| EP2976336A1 (en) | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| EP2976335A1 (en) | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| WO2014176475A2 (en) | 2013-04-26 | 2014-10-30 | The Regents Of The University Of Michigan | Egfr inhibitors and uses thereof |
| JP2016526540A (ja) | 2013-06-21 | 2016-09-05 | バイエル ファーマ アクチエンゲゼルシャフト | 置換ベンジルピラゾール |
| JP2016525076A (ja) | 2013-06-21 | 2016-08-22 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたベンジルピラゾール類 |
| CN105452237A (zh) | 2013-06-21 | 2016-03-30 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| WO2014202588A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| CA2928998A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| EP3143015B1 (en) | 2014-05-13 | 2019-02-20 | ARIAD Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| AR100886A1 (es) * | 2014-06-17 | 2016-11-09 | Bayer Pharma AG | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas |
| AU2016212230B2 (en) | 2015-01-28 | 2019-09-19 | Bayer Pharma Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CA2989469A1 (en) | 2015-06-17 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| US10308629B2 (en) | 2015-08-05 | 2019-06-04 | Bayer Pharma Aktiengesellschaft | 1H-pyrrol-3-amines |
| BR112018004175B8 (pt) | 2015-09-01 | 2023-10-31 | Taiho Pharmaceutical Co Ltd | Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto |
| EP3390401A1 (en) * | 2015-12-16 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones |
| MA46852A (fr) | 2016-11-17 | 2019-09-25 | Univ Texas | Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20 |
| CN111032655B (zh) | 2017-08-31 | 2022-09-02 | 达纳-法伯癌症研究所股份有限公司 | Egfr和/或her2抑制剂和使用方法 |
| US11339157B1 (en) | 2017-10-24 | 2022-05-24 | Bayer Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CA3091834A1 (en) | 2018-02-23 | 2019-08-29 | The Regents Of The University Of Michigan | Egfr dimer disruptors and use of the same |
| WO2019165385A1 (en) | 2018-02-23 | 2019-08-29 | Fulton Group N.A., Inc. | Inward-firing premix fuel combustion burner |
| WO2019241715A1 (en) | 2018-06-14 | 2019-12-19 | Dana-Farber Cancer Institute, Inc. | Cyano quinoline amide compounds as her2 inhibitors and methods of use |
| WO2019246541A1 (en) | 2018-06-21 | 2019-12-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| WO2020216773A1 (en) * | 2019-04-24 | 2020-10-29 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one compounds |
| GEAP202415804A (en) * | 2019-04-24 | 2024-02-12 | Bayer Ag | 4h-pyrrolo[3,2-c]pyridin-4-one compounds |
| EP3958865B1 (en) * | 2019-04-24 | 2025-12-10 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
-
2021
- 2021-09-22 IL IL301532A patent/IL301532A/en unknown
- 2021-09-22 CA CA3196712A patent/CA3196712A1/en active Pending
- 2021-09-22 EP EP21791189.0A patent/EP4217070A1/en active Pending
- 2021-09-22 MX MX2023003362A patent/MX2023003362A/es unknown
- 2021-09-22 US US18/027,316 patent/US20230364070A1/en active Pending
- 2021-09-22 WO PCT/US2021/051504 patent/WO2022066734A1/en not_active Ceased
- 2021-09-22 AU AU2021347288A patent/AU2021347288A1/en active Pending
- 2021-09-22 KR KR1020237013431A patent/KR20230094197A/ko active Pending
- 2021-09-22 JP JP2023542834A patent/JP7797513B2/ja active Active
- 2021-09-23 TW TW110135434A patent/TW202229272A/zh unknown
-
2023
- 2023-03-23 CL CL2023000856A patent/CL2023000856A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11155563B2 (en) | Macrocyclic compounds and uses thereof | |
| JP7466795B2 (ja) | Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン | |
| DK3140303T3 (en) | IMIDAZO [4,5-C] QUINOLIN-2 COMPOUNDS AND ITS USE IN TREATMENT OF CANCER | |
| AU2023302139A1 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| US20260083750A1 (en) | Small molecule inhibitors of kras proteins | |
| JP2024543879A (ja) | Ｋｒａｓ変異型タンパク質の小分子阻害剤 | |
| KR102520543B1 (ko) | 피리딘 화합물 | |
| JP7797513B2 (ja) | がんの処置に有用なピロロ［３，２－ｃ］ピリジン－４－オン誘導体 | |
| WO2024218686A1 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| US20250136615A1 (en) | Small molecule inhibitors of kras proteins | |
| JP2024521979A (ja) | Ｋｒａｓ変異タンパク質の小分子阻害剤関連出願の相互参照 | |
| TW201920150A (zh) | 作為jak激酶抑制劑之吡唑并及三唑并雙環化合物 | |
| JP2019501873A (ja) | イミダゾ［４，５−ｃ］キノリン−２−オン化合物及び癌の治療におけるその使用 | |
| JPWO2022066734A5 (https=) | ||
| JPWO2022076831A5 (https=) | ||
| JP2023526443A (ja) | Ｒｏｎ変異が関与する非小細胞肺がんの予防又は治療用医薬組成物及びその使用方法 | |
| JP2024047569A (ja) | Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン | |
| CA3212212A1 (en) | Cyclic compounds and methods of using same | |
| EA040712B1 (ru) | Макроциклические соединения и их использование |